Neulasta-controlled Trial of F-627 in Women With Breast Cancer Receiving Myelotoxic Chemotherapy
Status:
Completed
Trial end date:
2020-03-05
Target enrollment:
Participant gender:
Summary
This is a randomized, multi-center, single dose, open-label and Neulasta controlled phase 3
study to evaluate the efficacy and safety of F-627 in women with Stage I - III invasive
breast cancer receiving chemotherapy treatment.